Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Duchenne muscular dystrophy (DMD) is a progressive muscle‐wasting disease caused by mutations in the dystrophin gene, which leads to structural instability of the dystrophin–glycoprotein‐complex with subsequent muscle degeneration. In addition, muscle inflammation has been implicated in disease progression and therapeutically addressed with glucocorticosteroids. These have numerous adverse effects. Treatment with human immunoglobulin G (IgG) improved clinical and para‐clinical parameters in the early disease phase in the well‐established <i>mdx </i> mouse model. The aim of the present study was to confirm the efficacy of IgG in a long‐term pre‐clinical study in <i>mdx </i> mice. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>IgG (2 g/kg body weight) or NaCl solution as control was administered monthly over 18 months by intraperitoneal injection in <i>mdx </i> mice beginning at 3 weeks of age. Several clinical outcome measures including endurance, muscle strength, and echocardiography were assessed. After 18 months, the animals were sacrificed, blood was collected for analysis, and muscle samples were obtained for <i>ex vivo </i> muscle contraction tests, quantitative PCR, and histology. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>IgG significantly improved the daily voluntary running performance (1.9 m more total daily running distance, <i>P </i> < 0.0001) and slowed the decrease in grip strength by 0.1 mN, (<i>P </i> = 0.018). IgG reduced fatigability of the diaphragm (improved ratio to maximum force by 0.09 ± 0.04, <i>P </i> = 0.044), but specific tetanic force remained unchanged in the <i>ex vivo </i> muscle contraction test. Cardiac function was significantly better after IgG, especially fractional area shortening (<i>P </i> = 0.012). These results were accompanied by a reduction in cardiac fibrosis and the infiltration of T cells (<i>P </i> = 0.0002) and macrophages (<i>P </i> = 0.0027). In addition, treatment with IgG resulted in a significant reduction of the infiltration of T cells (<i>P </i> ≤ 0.036) in the diaphragm, gastrocnemius, quadriceps, and a similar trend in tibialis anterior and macrophages (<i>P </i> ≤ 0.045) in gastrocnemius, quadriceps, tibialis anterior, and a similar trend in the diaphragm, as well as a decrease in myopathic changes as reflected by a reduced central nuclear index in the diaphragm, tibialis anterior, and quadriceps (<i>P </i> ≤ 0.002 in all). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The present study underscores the importance of an inflammatory contribution to the disease progression of DMD. The data demonstrate the long‐term efficacy of IgG in the <i>mdx </i> mouse. IgG is well tolerated by humans and could preferentially complement gene therapy in DMD. The data call for a clinical trial with IgG in DMD. </p></section>

Immunohistological Changes In Dilated Cardiomyopathy Induced By Immunoadsorption Therapy And Subsequent Immunoglobulin Substitution

[Effect of Intravenous Immunoglobulin and Vitamin C on Progression of Experimental Autoimmune Myocarditis in Mice].

Multicentre, randomized, double‐blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO‐DCM): Rationale and design

Therapy with Immuoglobulin Ameliorates Giant Cell Myocarditis in Rats

Effects of Autoantibodies Removed by Immunoadsorption from Patients with Dilated Cardiomyopathy on Neonatal Rat Cardiomyocytes

[A Prospective, Randomized, Controlled Trial of Autologous Mesenchymal Stem Cells Transplantation for Dilated Cardiomyopathy].

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Molecular mechanisms behind progressing chronic inflammatory dilated cardiomyopathy

Adenovirus-mediated ICOSIg gene transfer alleviates cardiac remodeling in experimental autoimmune myocarditis.

Immunoglobulin Treatment Suppressed Adoptively Transferred Autoimmune Myocarditis in Severe Combined Immunodeficient Mice.

Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy

Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy

From Cardiac Myosin to the Beta Receptor: Autoantibodies Promote a Fibrotic Transcriptome and Reduced Ventricular Recovery in Human Myocarditis

Molecular mechanisms promoting progression of autoimmune myocarditis to dilated cardiomyopathy.

Immunoadsorption therapy in late-onset myasthenia gravis

Cardiosphere-Derived Cells Attenuate Inflammation, Preserve Systolic Function, and Prevent Adverse Remodeling in Rat Hearts With Experimental Autoimmune Myocarditis

Intravenous immunoglobulins in children with new onset dilated cardiomyopathy

Long‐term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy

Pathogenesis and therapy of autoimmunity-induced dilated cardiomyopathy.

The short-term efficacy and safety of HA280 immunoadsorption column in patients with idiopathic inflammatory myopathies

Treatment and Prevention of Experimental Autoimmune Myocarditis with CD28 Superagonists.